Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Phase 2 biomarker trial participants who completed 156 weeks of treatment were offered enrollment into another 52-week extension to continue to observe safety, assessments of plasma biomarkers, and cognitive effects, among others.

Alzheon Initiates Open-Label Extensions for Phase 2 and 3 Studies of Alzheimer Agent ALZ-801

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Michael Rogawski, MD, PhD. [LISTEN TIME: 12 minutes]

Special Episode: FDA Approves Diazepam Buccal Film for Pediatric Seizures

Videos

The neurologist at Mass General Hospital talked about leveraging artificial intelligence to enhance clinical practice amidst growing demands and workforce shortages in neurology. [WATCH TIME: 4 minutes]

Leveraging Artificial Intelligence to Redefine Clinical Efficacy and Empower Neurologists: Lidia Maria Veras Rocha Moura, MD, PhD, MPH, FAAN

In the phase 3 OCARINA 2 trial, subcutaneous ocrelizumab was non-inferior to intravenous infusion based on concentration levels in the blood, as well as comparable efficacy on relapses and brain lesions.

Ocrelizumab Gains EU CHMP Positive Opinion for Subcutaneous Formulation to Treat MS

The award ceremony is supported by EMD Serono and Viatris and will take place on Thursday, May 30, 2024, at the Nashville Music City Center in Nashville, Tennessee, during the 2024 CMSC Annual Meeting.

NeurologyLive and CMSC Announce the 3rd Annual Giants of MS Class of Inductees

, has been with the team since September 2022. Follow her on Twitter 

The professor of neurology at Mayo Clinic talked about the need for comprehensive testing, careful consideration of criteria for diagnosis, and effective treatment in MOG antibody-associated disease.

NeuroVoices: Eoin P. Flanagan, MB, BCh, on the Potential Significance of Spinal Fluid Testing for MOGAD Diagnosis

The professor of neurology at Mayo Clinic discussed the importance of standardizing MOG- antibody testing techniques and the need for effective treatments in patients living with MOGAD. [WATCH TIME: 3 minutes]

MOG-Antibody Testing and the Search for Effective Treatment in MOGAD: Eoin P. Flanagan, MB, BCh

The professor of neurology at Mayo Clinic talked about MOG-antibody associated disease, a relatively newly recognized demyelinating condition of the central nervous system. [WATCH TIME: 4 minutes]

Understanding MOG-Antibody Associated Disease in Clinical Research: Eoin P. Flanagan, MB, BCh

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

Gary Owens, MS

Articles